Up-regulation of hepatic low-density lipoprotein receptor-related protein 1: A possible novel mechanism of antiatherogenic activity of hydroxymethylglutaryl-coenzyme A reductase inhibitor: Atorvastatin and hepatic LRP1 expression

Metabolism: Clinical and Experimental

Volumn 60, Issue 7, 2011, Pages 930-940

  Moon, Jae Hoon ^a   Kang, Saet Byol ^a   Park, Jong Suk ^a   Lee, Byung Wan ^a   Kang, Eun Seok ^a   Ahn, Chul Woo ^a   Lee, Hyun Chul ^a   Cha, Bong Soo ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; LOW DENSITY LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; SMALL INTERFERING RNA; STEROL; STEROL REGULATORY ELEMENT BINDING PROTEIN 2;

ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LEVEL; CELL LINE; CELL STRAIN HEP3B; CELL STRAIN HEPG2; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPID DIET; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR UPREGULATION; TREATMENT DURATION;

ANIMALS; ANTIGENS, CD; ATHEROSCLEROSIS; DIETARY FATS; HEP G2 CELLS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LDL-RECEPTOR RELATED PROTEIN 1; LIPOPROTEINS, LDL; LIVER; PYRROLES; RATS; RATS, LONG-EVANS; RATS, SPRAGUE-DAWLEY; RNA, SMALL INTERFERING; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; STEROL REGULATORY ELEMENT BINDING PROTEINS; UP-REGULATION;

EID: 79959361457     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2010.08.013     Document Type: Article

References (37)

1. Herz J, Strickland DK. LRP: a multifunctional scavenger and signaling receptor. J Clin Invest 2001;108:779-84. (Pubitemid 32880284)
2. Beisiegel U, Weber W, Ihrke G, et al. The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein. Nature 1989; 341:162-4. (Pubitemid 19222781)
3. Rohlmann A, Gotthardt M, Hammer RE, et al. Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J Clin Invest 1998;101:689-95. (Pubitemid 28084254)
4. Willnow TE, Sheng Z, Ishibashi S, et al. Inhibition of hepatic chylomicron remnant uptake by gene transfer of a receptor antagonist. Science 1994;264:1471-4. (Pubitemid 24217140)
5. Hiki M, Shimada K, Ohmura H, et al. Serum levels of remnant lipoprotein cholesterol and oxidized low-density lipoprotein in patients with coronary artery disease. J Cardiol 2009;53:108-16.
6. Nakamura T, Obata JE, Takano H, et al. High serum levels of remnant lipoproteins predict ischemic stroke in patients with metabolic syndrome and mild carotid atherosclerosis. Atherosclerosis 2009; 202:234-40.
7. Nakajima K, Nakajima Y, Takeichi S, et al. Plasma remnant-like lipoprotein particles or LDL-C as major pathologic factors in sudden cardiac death cases. Atherosclerosis 2008;198:237-46. (Pubitemid 351406359)
8. Fujioka Y, Ishikawa Y. Remnant lipoproteins as strong key particles to atherogenesis. J Atheroscler Thromb 2009;16:145-54.
9. Liu L, Wen T, Zheng XY, et al. Remnant-like particles accelerate endothelial progenitor cells senescence and induce cellular dysfunction via an oxidative mechanism. Atherosclerosis 2009;202:405-14.
10. Zheng XY, Liu L. Remnant-like lipoprotein particles impair endothelial function: direct and indirect effects on nitric oxide synthase. J Lipid Res 2007;48:1673-80. (Pubitemid 47311984)
11. Nakajima K, Nakano T, Tanaka A. The oxidative modification hypothesis of atherosclerosis: the comparison of atherogenic effects on oxidized LDL and remnant lipoproteins in plasma. Clin Chim Acta 2006;367:36-47.
12. Watanabe N, Taniguchi T, Taketoh H, et al. Elevated remnant-like lipoprotein particles in impaired glucose tolerance and type 2 diabetic patients. Diabetes Care 1999;22:152-6. (Pubitemid 29028313)
13. Schaefer EJ, McNamara JR, Shah PK, et al. Elevated remnant-like particle cholesterol and triglyceride levels in diabetic men and women in the Framingham Offspring Study. Diabetes Care 2002;25:989-94. (Pubitemid 41110483)
14. Hirany S, O'Byrne D, Devaraj S, et al. Remnant-like particle-cholesterol concentrations in patients with type 2 diabetes mellitus and end-stage renal disease. Clin Chem 2000;46:667-72. (Pubitemid 30318422)
15. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232:34-47. (Pubitemid 16037973)
16. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997;89:331-40. (Pubitemid 27220877)
17. Standards of medical care in diabetes - 2009. Diabetes Care 2009;32 (Suppl 1):S13-S61.
18. Otokozawa S, Ai M, Van Himbergen T, et al. Effects of intensive atorvastatin and rosuvastatin treatment on apolipoprotein B-48 and remnant lipoprotein cholesterol levels. Atherosclerosis 2009; 205:197-201.
19. Ikewaki K, Terao Y, Ozasa H, et al. Effects of atorvastatin on nuclear magnetic resonance-defined lipoprotein subclasses and inflammatory markers in patients with hypercholesterolemia. J Atheroscler Thromb 2009;16:51-6.
20. Schaefer EJ, McNamara JR, Tayler T, et al. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects. Am J Cardiol 2004;93:31-9. (Pubitemid 38022030)
21. de Sauvage Nolting PR, Twickler MB, Dallinga-Thie GM, et al. Elevated remnant-like particles in heterozygous familial hypercholesterolemia and response to statin therapy. Circulation 2002;106: 788-92.
22. Kazama H, Usui S, Okazaki M, et al. Effects of bezafibrate and pravastatin on remnant-like lipoprotein particles and lipoprotein subclasses in type 2 diabetes. Diabetes Res Clin Pract 2003;59:181-9. (Pubitemid 36183301)
23. Sone H, Takahashi A, Shimano H, et al. HMG-CoA reductase inhibitor decreases small dense low-density lipoprotein and remnant-like particle cholesterol in patients with type-2 diabetes. Life Sci 2002; 71:2403-12. (Pubitemid 35264612)
24. Stein DT, Devaraj S, Balis D, et al. Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2001;21:2026-31. (Pubitemid 34219757)
25. Scharnagl H, Schinker R, Gierens H, et al. Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells. Biochem Pharmacol 2001;62:1545-55. (Pubitemid 33145298)
26. Kim S, Kim CH, Vaziri ND. Upregulation of hepatic LDL receptor-related protein in nephrotic syndrome: response to statin therapy. Am J Physiol Endocrinol Metab 2005;288:E813-7.
27. Rashid S, Curtis DE, Garuti R, et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A 2005;102:5374-9. (Pubitemid 40530265)
28. Cooper AD. Hepatic uptake of chylomicron remnants. J Lipid Res 1997;38:2173-92. (Pubitemid 27495377)
29. Kutt H, Herz J, Stanley KK. Structure of the low-density lipoprotein receptor-related protein (LRP) promoter. Biochim Biophys Acta 1989; 1009:229-36. (Pubitemid 20014813)
30. Gaeta BA, Borthwick I, Stanley KK. The 5′-flanking region of the alpha 2MR/LRP gene contains an enhancer-like cluster of Sp1 binding sites. Biochim Biophys Acta 1994;1219:307-13.
31. Llorente-Cortes V, Otero-Vinas M, Sanchez S, et al. Low-density lipoprotein upregulates low-density lipoprotein receptor-related protein expression in vascular smooth muscle cells: possible involvement of sterol regulatory element binding protein-2-dependent mechanism. Circulation 2002;106:3104-10. (Pubitemid 35440296)
32. Llorente-Cortes V, Costales P, Bernues J, et al. Sterol regulatory element-binding protein-2 negatively regulates low density lipoprotein receptor-related protein transcription. J Mol Biol 2006; 359:950-60. (Pubitemid 43831923)
33. Llorente-Cortes V, Royo T, Otero-Vinas M, et al. Sterol regulatory element binding proteins downregulate LDL receptor-related protein (LRP1) expression and LRP1-mediated aggregated LDL uptake by human macrophages. Cardiovasc Res 2007;74:526-36. (Pubitemid 46693710)
34. Llorente-Cortes V, Badimon L. LDL receptor-related protein and the vascular wall: implications for atherothrombosis. Arterioscler Thromb Vasc Biol 2005;25:497-504. (Pubitemid 40315669)
35. Laatsch A, Merkel M, Talmud PJ, et al. Insulin stimulates hepatic low density lipoprotein receptor-related protein 1 (LRP1) to increase postprandial lipoprotein clearance. Atherosclerosis 2009;204:105-11.
36. Benjannet S, Rhainds D, Essalmani R, et al. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem 2004; 279:48865-75. (Pubitemid 39625767)
37. Jeong HJ, Lee HS, Kim KS, et al. Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterolregulatory element binding protein-2. J Lipid Res 2008;49:399-409.